Abstract: Animal and seed based triglycerides are oils used in cosmetics, pharmaceuticals, animal feed, energy generation, etc. These triglycerides or glycerol esters are a mixture of triglycerides and free fatty esters (FFA) along with unsaponifiables and gums (MIU). FFA may range from very low, 1% or less, to more than 40% in some rendered animal oils. Corn oil from the wet or dry process of ethanol production may have from 7 to 15% FFA. The varying amount of FFA presents numerous process issues for downstream users of these oils especially in the production of biodiesel, fatty acid methyl ester (FAME). FFA about 1 or 2% requires esterification as well as transesterification for the production of FAME. What is needed is a method to perform Glycerolysis. This disclosure describes an improved catalyst system as well as process equipment and operating conditions to allow economical commercialization of Glycerolysis.

Abstract: Systems and apparatus are disclosed for a hinged low profile modular electrical power bar of a vehicle. An example disclosed vehicle power bar includes a connector including first and second sockets. The vehicle power bar also includes first and second pins. Additionally, the vehicle power bar includes a first busbar rotatably coupled to the connector via the first pin coupled to a first terminal of the first busbar and inserted into the first socket, and a second busbar rotatably coupled to the connector via the second pin coupled to a second terminal of the second busbar and inserted into the second socket.

Abstract: Animal and seed based triglycerides are oils used in cosmetics, pharmaceuticals, animal feed, energy generation, etc. These triglycerides or glycerol esters are a mixture of triglycerides and free fatty esters (FFA) along with unsaponifiables and gums (MIU). FFA may range from very low, 1% or less, to more than 40% in some rendered animal oils. Corn oil from the wet or dry process of ethanol production may have from 7 to 15% FFA. The varying amount of FFA presents numerous process issues for downstream users of these oils especially in the production of biodiesel, fatty acid methyl ester (FAME). FFA about 1 or 2% requires esterification as well as transesterification for the production of FAME. What is needed is a method to perform Glycerolysis. This disclosure describes an improved catalyst system as well as process equipment and operating conditions to allow economical commercialization of Glycerolysis.

Abstract: Devices and systems provide methods of detecting a severity change in respiratory insufficiency (RI) or chronic obstructive pulmonary disease (COPD) condition of a patient. In an example embodiment, a detection monitoring device determines one or more severity change indicators based on a measure of supplied pressure or other representative measure determined by the device. The supplied pressure may optionally be determined during pressure treatment that satisfies a target ventilation. The supplied pressure or representative data may be compared to one or more thresholds that are selected to represent a change in the condition of the RI or COPD patient such as an exacerbation of a prior condition. Results of the comparisons may trigger one or more warnings or messages to notify a patient or physician of a pending change to the patient's RI or COPD condition so that the patient may more immediately seek medical attention to treat the condition.

Abstract: Method, systems, and apparatus are disclosed for fused-wire cable connectors for a busbar. An example cable includes wires, insulation around the wires, and a connector extending from the wires beyond the insulation. The example connector is formed from ends of the wires that are fused together. The example connector defines an aperture that is to receive a fastener to couple the connector to a busbar.

Abstract: Devices and systems provide methods of detecting a severity change in respiratory insufficiency (RI) or chronic obstructive pulmonary disease (COPD) condition of a patient. In an example embodiment, a detection monitoring device determines one or more severity change indicators based on a measure of supplied pressure or other representative measure determined by the device. The supplied pressure may optionally be determined during pressure treatment that satisfies a target ventilation. The supplied pressure or representative data may be compared to one or more thresholds that are selected to represent a change in the condition of the RI or COPD patient such as an exacerbation of a prior condition. Results of the comparisons may trigger one or more warnings or messages to notify a patient or physician of a pending change to the patient's RI or COPD condition so that the patient may more immediately seek medical attention to treat the condition.

Abstract: An economical method to remove oil, silica, boron, arsenic and selenium from water produced from oil production or fracking operations. The pH is not altered during the process and post method water quality is sufficiently pure for irrigation use and use as potable drinking water. The method includes using filtration to reduce the size of the inorganic and organic undissolved solids to a size of particulates of less than 2 microns, removal of oil with a micro-oil droplet separator followed by pre-activated charcoal, treatment of boron with a selective group of polyols, and reverse osmosis.

Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising; the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

Abstract: Methods and apparatus for assessing the condition of and treating patients for heart failure by the delivery of continuous positive airway pressure are disclosed. Treatment of obstruction due to reflex vocal cord closure often experienced by heart failure patients is distinguished from treatment of upper airway obstruction typically associated with Obstructive Sleep Disorder. Treatment may also be implemented by delivering synchronized cardiac pressure oscillations superimposed on a respiratory pressure level to provide assistance for the heart. Heart treatment pressure dose indicator may be calculated for prescribing and monitoring the delivery of treatment. The apparatus may also generate data to track heart failure condition that may be indicative of the degree of severity of heart failure based upon breathing patterns to assist in the diagnosis and management of heart failure patients.

Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.

Abstract: A method of fractionating biomass, by permeability conditioning biomass suspended in a pH adjusted solution of at least one water-based polar solvent to form a conditioned biomass, intimately contacting the pH adjusted solution with at least one non-polar solvent, partitioning to obtain an non-polar solvent solution and a polar biomass solution, and recovering cell and cell derived products from the non-polar solvent solution and polar biomass solution. Products recovered from the above method. A method of operating a renewable and sustainable plant for growing and processing algae.

Abstract: Methods and apparatus for assessing the condition of and treating patients for heart failure by the delivery of continuous positive airway pressure are disclosed. Treatment of obstruction due to reflex vocal cord closure often experienced by heart failure patients is distinguished from treatment of upper airway obstruction typically associated with Obstructive Sleep Disorder. Treatment may also be implemented by delivering synchronized cardiac pressure oscillations superimposed on a respiratory pressure level to provide assistance for the heart. Heart treatment pressure dose indicator may be calculated for prescribing and monitoring the delivery of treatment. The apparatus may also generate data to track heart failure condition that may be indicative of the degree of severity of heart failure based upon breathing patterns to assist in the diagnosis and management of heart failure patients.

Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

Abstract: A camera system includes a lens that directs light onto an image sensor, an actuator that vibrates the lens, and a charge generator that charges a surface of the lens. The camera system further includes a controller that can determine a change in transparency of the lens and selectively activate the actuator based at least in part on the change in transparency. A method includes electrically charging a surface of a camera lens, determining a change in transparency of the camera lens, comparing the change in transparency to a predetermined threshold, and selectively activating an actuator to vibrate the camera lens if the change in transparency is above a predetermined threshold.

Abstract: The present invention relates to a process, which is particularly suitable for the production of sebacic acid and/or 2-octanol, and also for the production of biodiesel, wherein the process is a process for the reaction of a fatty acid ester (such as castor oil, or canola or rapeseed oil) and/or a fatty acid (such as riconleic acid) with an inorganic base (such as sodium hydroxide), the process comprising the following steps: (i) providing a pressurised and heated stream of fatty acid ester and/or fatty acid; (ii) providing an inorganic base; (iii) combining the stream obtained from step (i) with the inorganic base obtained in step (ii), in the presence of water, in a reaction vessel, by injection, thereby to produce reaction mixture in the form of a pressurised and heated stream; (iv) optionally maintaining the stream obtained in step (iii) at a selected temperature and pressure; and (v) thereby obtaining a reaction product.

Abstract: A therapy system configured to wash out or flush out the oral and/or nasal cavity to reduce the effective dead space and reduce the work of breathing. The system may displace the expired air in the oral and/or nasal cavity with atmospheric air, or air with altered concentrations, for example, increased humidity, or oxygen levels. A sealed oral interface is provided to the mouth of a patient to supply a volume of pressurized gas. A control system to synchronize the supply of pressurized gas with the patients respiratory cycle. The supply of respiratory gas may be provided during only a portion of the respiratory cycle.